Table 1. Characteristics of the 242 patients enrolled in phase I clinical trials during the period studied.
| Characteristic | No. (%) |
|---|---|
| Median age (range) | 64 years (27-79 years) |
| Race/ethnicity | |
| White | 194 (80) |
| African-American | 20 (8) |
| Hispanic | 12 (5) |
| Asian | 16 (7) |
| Pathologic diagnosis (all high-grade) | |
| Serous carcinoma | 192 (79) |
| Clear cell carcinoma | 24 (10) |
| Poorly differentiated/undifferentiated carcinoma | 19 (8) |
| Endometrioid carcinoma | 7 (3) |
| Initial disease stage | |
| I-II | 23 (10) |
| III-IV | 219 (90) |
| Eastern Cooperative Oncology Group performance status | |
| 0 | 66 (27) |
| ≥1 | 176 (73) |
| Lactate dehydrogenase | |
| Normal | 143 (59) |
| Above normal | 99 (41) |
| Albumin | |
| ≥3.5 g/dL | 214 (88) |
| <3.5 g/dL | 28 (12) |
| Metastatic sites | |
| ≤2 | 156 (64) |
| >2 | 86 (36) |
| Prior anti-angiogenic therapy | |
| Yes | 123 (51) |
| No | 119 (49) |
| Prior systemic therapy | |
| 1 prior line | 21 (9) |
| 2 prior lines | 30 (12) |
| ≥3 prior lines | 191 (79) |
| Median no. of prior therapies (range) | 4 (1-16) |
| No. of phase I protocols enrolled | |
| 1 | 161 (67) |
| ≥2 | 81 (33) |